Covid-19 vaccine manufacturing, said that it could begin late-stage clinical trials of Russia's potential coronavirus vaccine in the next few weeks, an executive said."Indian trials of the Sputnik-V vaccine candidate, being developed by Russia's sovereign wealth fund, will enroll 1,000-2,000 participants and be conducted at multiple government and private hospitals across the country," Deepak Sapra, CEO for API and pharmaceutical services at Dr.
Reddy's, told Reuters."We want to get to the first step - which is the commencement of the clinical trials by getting the necessary approvals from the Indian regulators - within the next few weeks," Sapra said to Reuters.The trials are part of a deal between the Russian Direct Investment Fund (RDIF).